JPRN-jRCT1080224637
Recruiting
未知
Biomarker study auxiliary to a multi-center phase I/II study of cabozantinib and panitumumab combination therapy or cabozantinib monotherapy in patients with MET amplified metastatic colorectal cancer (short title: METBEIGE study)
ational Cancer Center Hospital East0 sites54 target enrollmentApril 12, 2019
Conditionscolorectal cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- colorectal cancer
- Sponsor
- ational Cancer Center Hospital East
- Enrollment
- 54
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who are enrolled in the main study and personally provided written consent after adequately explained about the contents of the additional study
Exclusion Criteria
- •Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositisjuvenile dermatomyositisrheumatic muscle disease1000381610028302NL-OMON50706niversitair Medisch Centrum Utrecht365
Completed
Not Applicable
A Multicenter Study on Biomarker Development Utilizing AI Multiomics for Patients with Advanced Solid Malignant TumorsAdvanced Solid MalignanciesJPRN-UMIN000043899ational Cancer Center Hospital East2,768
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer patients with ESR1 mutations in cellfree DNAbreast cancer, metastasis, ESR1 mutations, chemotherapyNL-OMON25511Erasmus MC Cancer Institute, department of Medical Oncology185
Recruiting
Not Applicable
A single arm multicenter biomarker study determining the response to taxane-based chemotherapy in metastatic breast cancer (MBC) patients with ESR1 mutations in cell-free DNA: TAX-ESR1 study.Metastasis of breast cancer10006291NL-OMON46354Erasmus MC, Universitair Medisch Centrum Rotterdam175
Completed
Not Applicable
Study on biomarkers for the effect and safety of the treatment with Atezolizumab + Bevacizumab for liver cancerunresectable advanced hepatocellular carcinomaJPRN-UMIN000047758agoya University Graduate School of Medicine99